OBJECTIIVES: Using MDCA approach to evaluate the main attributes impact on the clinical efficacy and analyzes the strengths and weakness between FVIII treatment on-demand and prophylaxis in order to make consensus building in Chinese clinical key opinion leaders. METHODS:  Ten attributes are selected to compare the clinical efficacy, health utility, economic burden and treatment compliance. The weight value was investigated from 31 top hematologists. The total scores and relative ratio in each attribute are calculated by using Microsoft Office Excel software. The number of scores in each attribute is at the range from 1 to 10. RESULTS:  The important attributes are reducing the number of bleedings, disability rate, and days of absenteeism from work/school, improve quality of life, return back to normal life, study and work (>0.10). However, the factor of reducing inhibitor development and the number of infusing per week is less importance (<0.10). The total scores in treatment on-demand is the lowest one (160.54), low-dose prophylactic therapy is in the middle (234.76), the highest score is standard prophylactic therapy (263.84). CONCLUSIONS:  MCDA method can be used on clinical decision making on selecting haemophilia therapy. General speaking, the cost of lifelong prophylaxis is much less than that of treatment on-demand. However, In China, although the cost of FVIII treatment on-demand can be reimbursed by basic medical insurance system and catastrophic insurance scheme, it is inequity; the ratio of reimbursement and ceiling threshold various region by region. Prophylaxis therapy is a cost-effective regimen if it can be started in childhood stage. The concept of prophylactic therapy needs to be further dissemination in patients, providers and third-party policy makers.